2024-512022-28-01
Recruiting
Phase 1
A randomized, single-blind, placebo-controlled, study to examine the safety, tolerability, and pharmacokinetics of M6229 administered as a 120-hour continuous infusion at two dose levels versus placebo in healthy subjects
Matisse Pharmaceuticals B.V.1 site in 1 country15 target enrollmentStarted: October 16, 2024Last updated:
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Matisse Pharmaceuticals B.V.
- Enrollment
- 15
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Clinical trial information desk”
Scientific
Matisse Pharmaceuticals B.V.
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
A randomised, single-blinded, placebo-controlled, multicentre study to investigate the pharmacodynamic effects of lithium on glycogen synthase kinase-3 (GSK-3) activity in patients with Alzheimer's diseaseISRCTN72046462AstraZeneca (Sweden)70
Active, not recruiting
Not Applicable
A randomized, single-blind, placebo-controlled, parallel-group study evaluating the anti-inflammatory activity of GSK315234 in synovial biopsy tissue obtained from subjects with rheumatoid arthritisRheumatoid arthritisMedDRA version: 12.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2009-012055-19-IEGlaxoSmithKline Research & Development Limited45
Active, not recruiting
Not Applicable
A randomized, single-blind, placebo-controlled, parallel-group study evaluating the anti-inflammatory activity of GSK315234 in synovial biopsy tissue obtained from subjects with rheumatoid arthritisRheumatoid arthritisMedDRA version: 12.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2009-012055-19-GBGlaxoSmithKline Research & Development Limited45
Recruiting
Not Applicable
To evaluate the efficacy andsafety of Nigellin in individuals with allergic rhinitisHealth Condition 1: - Health Condition 2: -CTRI/2022/07/044180Sami Sabinsa Group Limited
Completed
Not Applicable
Acute effects of hibiscus sabdariffa on cardiometabolic markers and cognitive functioReduction of blood pressureCirculatory SystemISRCTN14881129niversity of Leeds20